New Directions in Treatment of Hypoparathyroidism.

Abstract

The history of parathyroid hormone (PTH) replacement therapy for hypoparathyroidism begins in 1929. In 2015, the Food and Drug Administration approved recombinant human PTH(1-84) [rhPTH(1-84)] as a treatment for hypoparathyroidism. Long-term studies of rhPTH(1-84), up to 6 years, have demonstrated continued efficacy of this replacement agent. Approaches to optimize PTH treatment in hypoparathyroidism include subcutaneous pump delivery systems, long-lived carrier molecules, and long-acting PTH analogues that show promise to prolong efficacy. Calcilytic compounds have been explored as a treatment for autosomal dominant hypocalcemia. Calcilytics are negative modulators of the calcium-sensing receptor and may present a therapeutic opportunity to increase endogenous PTH synthesis and secretion.

• Authors: Gaia Tabacco, John P Bilezikian
• Journal: Endocrinology and metabolism clinics of North America (Endocrinol Metab Clin North Am) Vol. 47 Issue 4 Pg. 901-915 (12 2018) ISSN: 1558-4410 [Electronic] United States
• PMID: 30390821 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Review)
• Copyright: Copyright © 2018 Elsevier Inc. All rights reserved.

Chemical References

• PTH protein, human
• Parathyroid Hormone
• Recombinant Proteins

Topics

• Endocrinology (trends)
• Hormone Replacement Therapy
• Humans
• Hypoparathyroidism (therapy)
• Parathyroid Hormone (therapeutic use)
• Recombinant Proteins